RYTELO® (imetelstat) is indicated for treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia.

Dose reductions of RYTELO due to an adverse reaction occurred in 49% of patients. Adverse reactions which required dose reductions in > 2% of patients included neutropenia and thrombocytopenia.

RYTELO was studied to see whether patients treated with it would need fewer red blood cell transfusions compared to those who received treatment with no active medication (placebo). Nearly …

2026年5月3日 · Rytelo package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.

2026年4月22日 · RYTELO for injection contains imetelstat, an oligonucleotide telomerase inhibitor for intravenous use. Imetelstat sodium is a white to off-white or slightly yellow, amorphous, solid powder.

Medscape - Myelodysplastic syndrome dosing for Rytelo (imetelstat), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information.

Rytelo 188 mg powder for concentrate for solution for infusion is a clear, 10 mL Type 1 glass vial with a chlorobutyl rubber stopper and an aluminium flip-off seal with a royal blue plastic cap.

RYTELO (imetelstat) for injection is a sterile, preservative-free, white to off-white or slightly yellow lyophilized powder for intravenous infusion after reconstitution and dilution.

2024年9月9日 · Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Geron Corporation as a limited specialty pharmacy provider …

Learn how RYTELO (imetelstat) is dosed and administered to lower-risk myelodysplastic syndromes (MDS) patients with transfusion-dependent anemia.